Atsparumas antibiotikams ypač dėl gramneigiamų bakterijų, beveik susidarė į krizę panaši situacija. Naujasis antibiotikas Zosurabalpin (RG6006) rodo pažadus. Ikiklinikinių tyrimų metu nustatyta, kad jis veiksmingas prieš vaistams atsparias gramneigiamas bakterijas CRAB.
Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of antibiotikai to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of antibiotikas atsparumas.
Acinetobacter baumannii is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available antibiotikai. There is an urgent need for an effective antibiotikas against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective antibiotikas. A progress towards this goal has been reported.
Scientists have identified a novel class of antibiotikai namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
Zosurabalpinas (RG6006) yra antibiotikas candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-klinikinis trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame antibiotikas-resistance mechanism of CARB suggesting Zosurabalpinas turi potencialo.
Hence, human klinikinis trials have been initiated to check for safety and efficacy Zosurabalpinas gydant invazines KRAB sukeltas infekcijas.
***
Nuorodos:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel antibiotikas class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- Hawser S., et al 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against klinikinis Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
